| Title |
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion
|
|---|---|
| Published in |
Targeted Oncology, September 2019
|
| DOI | 10.1007/s11523-019-00669-x |
| Pubmed ID | |
| Authors |
Silvia La Monica, Roberta Minari, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Maricla Galetti, Graziana Digiacomo, Federica Riccardi, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 4 | 15% |
| Lecturer | 3 | 12% |
| Student > Ph. D. Student | 3 | 12% |
| Researcher | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 8 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 6 | 23% |
| Medicine and Dentistry | 4 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Unspecified | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 10 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 June 2023.
All research outputs
#6,679,091
of 24,293,076 outputs
Outputs from Targeted Oncology
#98
of 578 outputs
Outputs of similar age
#113,066
of 344,650 outputs
Outputs of similar age from Targeted Oncology
#5
of 19 outputs
Altmetric has tracked 24,293,076 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 578 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,650 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.